The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis

Published:2019-07-09 Issue:21 Volume:125 Page:3776-3789
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rulli Eliana¹,Legramandi Lorenzo¹,Salvati Lorenzo²^ORCID,Mandala Mario³^ORCID

Affiliation:

1. Department of Oncology Mario Negri IRCCS Institute for Pharmacological Research Milan Italy

2. Department of Experimental and Clinical Medicine University of Florence Florence Italy

3. Unit of Medical Oncology, Department of Oncology and Hematology Pope John XXIII Cancer Center Hospital Bergamo Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32375

Reference38 articles.

1. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

2. Prognostic factors for survival in melanoma patients with brain metastases

3. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases

4. Clinical Management of Multiple Melanoma Brain Metastases

5. Determinants of Outcome in Melanoma Patients With Cerebral Metastases

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors;Molecules;2024-08-16

2. Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis;Neurosurgical Review;2024-08-14

3. Radiation and Melanoma: Where Are We Now?;Current Oncology Reports;2024-06-01

4. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey;Melanoma Research;2024-03-28

5. Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses;Applied Sciences;2024-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3